Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 9406 Dose Level IV

Reviewer: William Levin, MD
Ultima Vez Modificado: 11 de octubre del 2002

Presenter: J.M. Michalski
Presenter's Affiliation: Dept. of Radiation Oncology, Washington University Medical School, St. Louis, MO, USA
Type of Session: Scientific


  • Numerous previous studies have suggested that there is a dose-response relationship with radiation therapy (RT) used in the treatment of prostate cancer.
  • This study is a toxicity report on dose level IV (74 Gy) on RTOG 9406 for stage I&II adenocarcinoma of the prostate.

Materials and Methods

  • At a dose of 74 Gy, 256 pts are analyzable for toxicity.
  • 2 Gy/day fractions were used and the dose was prescribed to the planning treatment volume (PTV).
  • Patients were stratified according to risk of seminal vesicle involvement (SVI).
  • For those pts with <15% risk of SVI (Group I), PTV included the prostate, while those with a 15% or greater risk (Group II) had an initial PTV that included the prostate and SV?s to 54 Gy followed by a conedown to the prostate-only.


  • Mean follow-up for Groups I &II, were 24 months and 20 months, respectively.
  • Acute toxicity at this dose level was remarkably low, with grade 3 effects seen in 1% of the Group I pts and 3% of the Group II pts.
  • Late grade 3 toxicity was much lower than expected when compared to historic controls on previous RTOG trials.
  • For Group I, 1 pt had a late grade 3 or higher toxicity, while 18 pts were predicted by the historical data. (p<.0001)
  • For Group II, 5 pts had toxicity, while 20 were predicted. (p=.001)
  • There was a trend for increased toxicity when fraction size was greater than 2 Gy.

Author's Conclusions

  • Toxicity at the 74 Gy dose level was better than predicted by the historical data.
  • Longer follow-up is necessary to better assess late toxicity.

Clinical/Scientific Implications

  • Information on toxicity is very important as radiation doses are escalated in the treatment of prostate cancer.
  • As the authors point out, longer follow-up is necessary to assess safety and efficacy of dose escalation.

Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Ortho Biotech.


My Cancer Experience
by Bob Riter
October 06, 2015